Showing 1481-1490 of 4936 results for "".
Minimally Invasive Trends
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/minimally-invasive-trends/19055/Michael H. Gold, MD talks about the latest trends in minimally invasive procedures, including for rejuvenation of the neck.Update on Melanoma Detection and Screening
https://practicaldermatology.com/topics/skin-cancer-photoprotection/update-on-melanoma-detection-and-screening/19095/From full body skin exams to emerging tape-strip methods for melanoma diagnosis, Laura Ferris, MD talks about the latest research in skin cancer diagnosis with host Joshua Zeichner, MD.Curing the Blues: Resolution of the Tyndall Effect Through Removal of a Misplaced NASHA Filler with Hyaluronidase
https://practicaldermatology.com/topics/general-topics/PD0509_11-php/22833/Implantation of NASHA fillers too superficially can produce the Tyndall effect. Besides aesthetic elegance, longevity after injection and an excellent safety record, a significant advantage of NASHA fillers is that they are reversible when misplaced.Pearls for Choosing and Initiating Psoriasis Therapy
https://practicaldermatology.com/topics/psoriasis/PD0309_18-php/22872/Members of the psoriasis panel at the 2009 South Beach Symposium last month offered insights on patient care.Annual Meeting Highlights; Ortho Derm's New Cash Pay Model
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-annual-meeting-highlights-ortho-derm-s-new-cash-pay-model/19579/The annual meeting of the American Academy of Dermatology features updates in medical, surgical, and cosmetic dermatology. Practical Dermatology Chief medical editor Dr. Neal Bhatia highlighted the breadth of coverage at the meeting. DermTube caught up with multiple presenters who shared pearls fromConversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiUpdates from CSF, PsA Guidelines, Revance Data
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-updates-from-csf-psa-guidelines-revance-data/18200/Cosmetic Surgery Forum celebrates a decade of success. The meeting, featuring a panel of experts in both medical and cosmetic dermatology, wrapped up on Saturday and is already announcing plans for 2019. When it comes to psoriatic arthritis, prescribers should treat to target, new guidelines from thMedical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-medical-derm-at-summer-aad-novel-drugs-acne-at-derm-2018/18244/The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dAssessing the Aging Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/assessing-the-aging-face/18849/Jason Emer, MD discusses the evolving filler market and new trends in facial rejuvenation treatments. He offers tips for assessing patients globally—in three and four dimensions—in order to choose the right options for contouring the face with fillers and fat in order to give patients the most naturDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approve